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Abstract
Metastatic melanoma is a leading cause of death from skin diseases, and is often associated with activation of Wnt/b-catenin
signaling pathway. We have examined the inhibitory effect of silymarin, a plant flavanoid from Silybum marianum, on cell
migration of metastasis-specific human melanoma cell lines (A375 and Hs294t) and assessed whether Wnt/b-catenin
signaling is the target of silymarin. Using an in vitro invasion assay, we found that treatment of human melanoma cell lines
with silymarin resulted in concentration-dependent inhibition of cell migration, which was associated with accumulation of
cytosolic b-catenin, while reducing the nuclear accumulation of b-catenin (i.e., b-catenin inactivation) and reducing the
levels of matrix metalloproteinase (MMP) -2 and MMP-9 which are the down-stream targets of b-catenin. Silymarin
enhanced: (i) the levels of casein kinase 1a, glycogen synthase kinase-3b and phosphorylated-b-catenin on critical residues
Ser
45, Ser
33/37 and Thr
41, and (ii) the binding of b-transducin repeat-containing proteins (b-TrCP) with phospho forms of b-
catenin in melanoma cells. These events play important roles in degradation or inactivation of b-catenin. To verify whether
b-catenin is a potent molecular target of silymarin, the effect of silymarin was determined on b-catenin-activated (Mel 1241)
and b-catenin-inactivated (Mel 1011) melanoma cells. Treatment of Mel 1241 cells with silymarin or FH535, an inhibitor of
Wnt/b-catenin pathway, significantly inhibited cell migration of Mel 1241 cells, which was associated with the elevated
levels of casein kinase 1a and glycogen synthase kinase-3b, and decreased accumulation of nuclear b-catenin and inhibition
of MMP-2 and MMP-9 levels. However, this effect of silymarin and FH535 was not found in Mel 1011 melanoma cells. These
results indicate for the first time that silymarin inhibits melanoma cell migration by targeting b-catenin signaling pathway.
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Introduction
Melanoma is the leading cause of death from skin diseases due
to its propensity to metastasize. The overall incidence of
melanoma is increasing in US, and is increasing rapidly in
children. It accounted for an estimated 114,900 new cases of
melanoma which were diagnosed in the US for 2010, out of which
68,130 were invasive and resulted in death of nearly 8,700
individuals [1]. Although, melanoma is less common than other
types of skin cancer, however, it causes the majority (75%) of skin
cancer-related deaths. Activating mutations of the protooncogene
BRAF have been observed in approximately 50% of malignant
melanomas. However, BRAF mutations alone are insufficient to
cause malignant transformation and other triggering events are
needed for melanomagenesis. Once, diagnosed with metastatic
melanoma, most patients will ultimately die of their disease within
2 years [2]. Since, melanoma is a highly malignant cancer with a
potent capacity to metastasize distantly, an approach that
decreases its metastatic ability may facilitate the development of
an effective strategy for its treatment and/or prevention.
Phytochemicals offer promising options for the prevention of
cancer metastasis. Silymarin is one of them, and this flavanoid is
obtained from milk thistle (Silybum marianum L. Gaertn.) plant.
Silymarin is composed primarily of silibinin (<90%) together with
small amounts of other silibinin stereoisomers, such as isosilybin,
dihydrosilybin, silydianin and silychristin [3]. Because silymarin
has been shown to have anti-inflammatory, anti-oxidative and
anti-carcinogenic effects [4,5], it has been tested in various in vitro
and in vivo models for its efficacy in prevention of skin
carcinogenesis [5]. We previously have shown that topical
application of silymarin to sensitive-to-carcinogen (SENCAR)
mice resulted in inhibition of 7,12-dimethylbenz(a) anthracene-
initiated and 12-O-tetradecanoylphorbol-13-acetate-promoted
skin tumorigenesis in terms of tumor incidence, tumor multiplicity
and tumor growth [6]. We also have shown that topical
application of silymarin inhibits ultraviolet radiation-induced skin
carcinogenesis in SKH-1 hairless mice [4]. These studies indicated
that silymarin possesses potent anti-skin carcinogenic effects [4–6].
Importantly, the chemopreventive effect of silymarin has been
studied extensively on non-melanoma skin cancer but its effect on
melanoma has not been assessed.
Although the molecular mechanisms underlying the progression
of melanoma remain unresolved, various studies have implicated
constitutively active Wnt/b-catenin signaling in melanoma
progression and metastasis [7,8]. Non-phosphorylated b-catenin
accumulates in the cytoplasm, when activated it enters the nucleus
and interacts with T-cell factor transcription factors to control
various target genes that are involved in cellular proliferation and
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with late stages of tumor progression and metastasis. The presence
of mutated b-catenin is associated with aggressive tumor growth
and regulates expression of various target genes that mediate
cellular processes including proliferation, and migration [9,10]. In
the canonical model of Wnt signaling, b-catenin is phosphorylated
at certain key residues by glycogen synthase kinase-3b (GSK-3b)
and casein kinase 1 a (CK1a) leading to its ubiquitination and
subsequent degradation [11,12]. Like cancers of other organs, the
regulation of b-catenin is lost in melanoma [13–15]. This then
leads to nuclear accumulation of b-catenin and subsequent
stimulation of downstream target genes, which includes the genes
of cell proliferation (e.g., cyclins and c-myc) and cell invasion (e.g.,
matrix metalloproteinases) [16–18].
Since metastasis of melanoma is the leading cause of death in
humans, in the present study we assessed the chemotherapeutic
effects of silymarin on the migration/invasion potential of human
melanoma cells. For this purpose, two human metastasis-specific
cell lines were selected: A375 which is BRAF-mutated and another
Hs294t cell line which is also highly metastasis-specific but not
BRAF-mutated. Normal human epidermal melanocytes were used
as a control. In this study we assessed whether silymarin inhibits
the migration of melanoma cells and whether it is associated with
the inactivation of the b-catenin signaling pathway or decreased
accumulation of nuclear b-catenin. In order to verify the role of b-
catenin in suppression of melanoma cell migration by silymarin,
we compared the effect of silymarin on the behavior of two
different melanoma cell lines that differ in their states of
constitutive activation of Wnt/b-catenin signaling. The cell lines
used were: (a) Mel 1241 cells that are characterized by constitutive
activation of b-catenin, and (b) Mel 1011 cells which lack
constitutively active b-catenin pathway. Here, we present evidence
that silymarin inhibits the invasiveness or migratory potential of
melanoma cells by inactivation of b-catenin.
Materials and Methods
Cell lines and cell culture conditions
The human melanoma cells lines, A375 and Hs294t, were
purchased from the American Type Culture Collection (Manassas,
VA), while melanoma cells Mel 1241 and Mel 1011 were a kind
gift from Dr. Paul Robbins (Center of Cancer Research, National
Cancer Institute, Bethesda, MD). All the cell lines were cultured as
monolayers in Dulbecco’s modified Eagle’s medium, supplement-
ed with 10% heat-inactivated fetal bovine serum (Hyclone, Logan,
UT), 100 mg/ml penicillin and 100 mg/mL streptomycin and
maintained in an incubator with 5% CO2 at 37uC. Normal
human epidermal melanocytes (HEMa-LP, Cat. No. C-024-5C)
were obtained from Invitrogen (Carlsbad, CA), and were cultured
in HMGS-2 medium supplemented with human melanocyte
growth supplement provided by the supplier. For the treatment of
cells, silymarin was dissolved in a small amount of acetone, which
was added to the complete cell culture medium [maximum
concentration of acetone, 0.1% (v/v) in media] prior to addition to
subconfluent cells (60–70% confluent). Cells treated with acetone
alone served as a vehicle control.
Chemicals and antibodies
Purified silymarin was purchased from Sigma Chemical Co. (St
Louis, MO). The antibodies specific for b-catenin were purchased
from R&D Biosystems (Minneapolis, MN), while antibodies for
phospho b-catenin, CK1a, GSK-3b, matrix metalloproteinase
(MMP)-2, MMP-9, b-transducin repeat-containing proteins (b-
TrCP) and b-actin were obtained from Cell Signaling Technology
(Beverly, MA). Antibody specific to b-catenin for immunostaining
was obtained from R&D Biosystems (Minneapolis, MN). Respec-
tive secondary antibodies (rabbit anti-goat and goat anti-rabbit)
conjugated with horseradish peroxidase were purchased from
Santa Cruz Biotech (Santa Cruz, CA). Boyden Chambers and
polycarbonate membranes (8 mm pore size) for cell migration
assays were obtained from Neuroprobe (Gaithersburg, MD).
Cell proliferation assay
The effect of silymarin on the viability of melanoma cells was
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide assay (Sigma) or MTT assay, as previously described
[19]. A total of 1610
4 cells per well in 200 mL complete medium
were seeded in a 96-well plate and treated with silymarin as
previously described [19]. All treatment concentrations were
repeated in six wells.
Matrigel invasion assay
The migration capacity of melanoma cancer cells was
determined in vitro using Boyden Chambers in which the two
chambers were separated with matrigel coated Millipore mem-
branes (6.5 mm diameter filters, 8 mM pore size), as detailed
previously [20]. Briefly, melanoma cells (1.5610
4 cells/200 mL
serum-reduced medium) were placed in the upper chamber of
Boyden chambers. Test agents were added to the upper chamber
(200 mL) and the lower chamber contained the medium alone
(150 mL). Chambers were assembled and kept in an incubator for
24 h or 8 h. At the desired time point, cells from the upper surface
of Millipore membranes were removed with gentle swabbing and
the migrant cells on the lower surface of membranes were fixed
and stained with crystal violet. Membranes were then washed and
mounted onto glass slides. The membranes were examined
microscopically and cellular migration per sample was determined
by counting the number of stained cells in at least four to five
randomly selected fields visualized with an Olympus BX41
microscope. Data are presented as mean number of the migrating
cells 6 SD per microscopic field per sample. Each cell migration
experiment was repeated at least three times. Representative
photomicrographs were obtained using a Qcolor5 digital camera
system fitted to an Olympus BX41 microscope.
Scratch assay or wound healing assay
Wound healing assay was performed to detect melanoma cell
migration, as detailed previously [20]. Briefly, melanoma cells
were grown to full confluency in six-well plates and incubated
overnight in starvation medium. Cell monolayers were wounded
with a sterile 100 mL pipette tip, washed with starvation medium
to remove detached cells from the plates. Cells were left either
untreated or treated with indicated doses of silymarin in full
medium and kept in a CO2 incubator for 24 h. After 24 h,
medium was replaced with phosphate-buffered saline (PBS) buffer,
the wound gap was observed and cells were photographed using
an Olympus BX41 microscope fitted with digital camera.
Immunofluorescent detection of b-catenin
Human melanoma cells (A375 and Hs294t cells) were treated
with various concentrations of silymarin (0, 10, 20, and 40 mg/mL)
for the desired time period. The cells were then harvested and
processed for cytospin preparation (1610
5 cells/slide) for immu-
nofluorescent staining and detection of nuclear b-catenin. Briefly,
cells were fixed with methanol at 220uC for 10 minutes and non-
specific binding sites were blocked with 2% bovine serum albumin
(Sigma, St Louis, MO) in PBS for 30 min. Cells were
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MO) in PBS and then incubated with b-catenin-specific antibody
for 2 h at room temperature. The cells were washed with PBS
buffer and b-catenin was detected by an Alexa fluor 594-
conjugated secondary antibody. Cells were mounted with
Vectashield mounting medium for fluorescence and stained with
DAPI (Vector Laboratories, Burlingame, CA) before they were
observed with a fluorescence detection equipped microscope and
photographed.
Immunoprecipitation and immunoblotting
Following treatment of melanoma cells with or without
silymarin or other agents for the indicated time periods, the cells
were harvested, washed with cold PBS buffer and lysed with ice-
cold lysis buffer supplemented with protease inhibitors, as detailed
previously [20]. Nuclear and cytosolic fractions were also prepared
from the cells of different treatment groups following standard
protocols, as described earlier [20]. Equal amounts of proteins
from each treatment group were resolved on 10% Tris/Glycine
gels and transferred onto a nitrocellulose membrane. After
blocking the non-specific binding sites, the membrane was
incubated with the primary antibody at 4uC overnight. The
membrane was then incubated with the appropriate peroxidase-
conjugated secondary antibody and the immunoreactive bands
were visualized using the enhanced chemiluminescence reagents.
To verify equal protein loading, the membrane was stripped and
re-probed with anti-b actin antibody. Each experiment was
repeated at least three times for western blotting and representa-
tive blots are presented.
For b-TrCP binding assay, A375 melanoma cells were treated
with vehicle or various concentrations of silymarin for 24 h,
washed with ice-cold PBS, and whole cell lysates prepared as
described previously [20]. Aliquots containing 200 mg of protein
were cleared with protein A/G-plus agarose beads (Santa Cruz,
CA). b-TrCP protein was immunoprecipitated from whole cell
lysates by overnight incubation with anti-b-TrCP antibody at 4uC
followed by the addition of protein A/G-plus agarose beads
(50 mL, Santa Cruz, CA) and continued incubation for 2 h.
Immunoprecipitates were washed, and subsequently subjected to
SDS-PAGE on 10% gels followed by immunoblotting using
antibodies specific to phospho forms of b-catenin.
Statistical analysis
For migration assays, the control and silymarin-treatment
groups were compared using one-way analysis of variance
(ANOVA) followed by post hoc Dunn’s test using GraphPad Prism
version 4.00 for Windows, GraphPad Software, San Diego,
California, USA, www.graphpad.com. All quantitative data for
cell migration are shown as mean 6 SD/microscopic field, and
each experiment was repeated at least 3 times. In each case
P,0.05 was considered statistically significant.
Results
Comparative migratory behavior of human melanoma
cells and normal human epidermal melanocytes
First the studies were performed to examine the migratory
behavior of melanoma cells and normal human epidermal
melanocytes under identical conditions. For this purpose, cells
were kept in Boyden chambers for invasion assays for 24 h in an
incubator to assess their migration capability. As shown in
Figure 1A, the cell migration capacity of melanoma cells was
significantly higher (P,0.001) than normal human epidermal
melanocytes. The migration of A375 cells was greater than Hs294t
cells (390614 cells/microscopic field for A375 vs 340612 cells/
microscopic field for Hs294t). Under identical conditions,
migration of normal human epidermal melanocytes was signifi-
cantly lower (1964 cells per microscopic field, P,0.001) than
melanoma cells, as summarized in Figure 1B.
Silymarin inhibits human melanoma cell migration:
wound healing assay
Molecular structure of silibinin is shown in Figure 1C, which is a
major (90%) and most active component of silymarin. We first
determined whether treatment of A375 and Hs294t human
melanoma cells with silymarin inhibited their migration using a
wound healing assay, as described in Material and Methods. Before
conducting this assay, preliminary screening experiments were
performed to determine the effects of lower (low, non-death-inducing)
concentrations of silymarin (0–40 mg/mL) that did not induce cell
death in melanoma cells.As shown in Figure2A, relative to untreated
control cells, treatment of cells with various concentrations of
silymarin(0,10,20and40 mg/mL) reduced the migration capacity of
A375 and Hs294t cells in a concentration-dependent manner after
the treatment of cells for 24 h. The major part of gap or wounding
space between cell layers after making a wound was occupied by the
migrating A375 cells which were not treated with silymarin.
However, the healing of the wound or the empty space of the cells
was largely not occupied by the migrating cells treated with silymarin
and this effect was dose-dependent. The gap or wounding space
Figure 1. Migration ability of human melanoma cells and
normal human epidermal melanocytes. (A) Equal numbers of
human melanoma cells (A375 and Hs294t) and normal human
epidermal melanocytes (HEMa) were subjected to cell migration by
standard invasion assay using Boyden chambers. Twenty four h later,
migratory cells were detected on the membrane after staining the
migratory cells with the 0.1% crystal violet dye. Representative
photomicrographs are shown from three independent experiments.
(B) The migratory cells were counted and the results expressed as the
mean number of migratory cells 6 SD per microscopic field (n=3).
Significantly less migration of normal human melanocytes versus
melanoma cells,
*P,0.001. (C) Chemical structure of silibinin, the major
and most biological active component of silymarin.
doi:10.1371/journal.pone.0023000.g001
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Figure 2A. These observations suggest that silymarin inhibited the
migration ofmelanoma cells.To confirm that the inhibition of cancer
cell migration by silymarin was a direct effect on cell migration and
not due to a reduction in cell viability, a trypan blue assay was
performed using cells that were treated identically to those used in the
migration assays. Treatment of A375 and Hs294t cells with various
concentrations of silymarin (0, 10, 20 and 40 mg/mL) for 24 h had no
significant effect on cell viability or cell death (data not shown).
Silymarin inhibits melanoma cell invasion: Boyden
chamber assay
Since cell invasion is a key step involved in tumor metastasis,
inhibition of cell invasion by the use of phytochemicals, such as
silymarin, may represent an important strategy to prevent
melanoma metastasis. Therefore, we determined whether treat-
ment of A375 and Hs294t human melanoma cells with silymarin
inhibited their invasive potential using Boyden chamber cell
invasion assay. Again, preliminary screening experiments were
performed to determine the effects of lower concentrations of
silymarin that did not induce melanoma cell death (data not
shown). As shown in Figure 2B, relative to untreated control cells,
treatment with silymarin at concentrations of 10, 20 and 40 mg/
mL reduced the migratory capacity of A375 and Hs294t cells in a
concentration-dependent manner. The density of the migrating
cells on the membrane after staining with crystal violet is shown in
Figure 2B, and the numbers of migrating cells/microscopic field
are summarized in Figure 2C. The cell migration was inhibited by
Figure 2. Silymarin inhibits melanoma cell migration and/or invasion in a concentration-dependent manner. (A) Wound healing assay
was performed to assess the effect of silymarin on the migration of A375 and Hs294t human melanoma cells. Incubation of A375 or Hs294t cells with
silymarin for 24 h inhibits migration of cells in a concentration-dependent manner compared to non-silymarin-treated control cells. Broken red line
indicates the gap without the presence of cells. Assay was repeated three times and representative pictures are shown. (B) Treatment of human
melanoma cells with silymarin inhibits migration or invasion ability of cells. Treatment of A375 or Hs294t human melanoma cells with silymarin for
24 h inhibits invasion of cells in a concentration dependent manner. (C) The migratory cells were counted on membrane in at least four to five
randomly selected microscopic fields and the results are summarized and expressed as the mean number of migratory cells 6 SD per microscopic
field. Significant difference versus non-silymarin treated control group,
*P,0.001,
**P,0.01.
doi:10.1371/journal.pone.0023000.g002
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(P,0.0120.001) in Hs294t cells in a concentration-dependent
manner after treatment with silymarin for 24 h.
Silymarin reduces nuclear accumulation of b-catenin
Activation of b-catenin has been implicated in cancer cell
migration. Therefore, we determined the effect of silymarin on the
levels of b-catenin protein on both A375 and Hs294t cells using
western blot analysis. For this purpose cells were treated with
silymarin for 24 h and whole cell lysates, cytosolic and nuclear
fractions were prepared. Western blot analysis revealed that
treatment of A375 and Hs294t cells with silymarin for 24 h
resulted in reduction of b-catenin levels in the nucleus of the cells
(Figures 3A and 3D). This change correlated with an increase in
cytosolic b-catenin. These observations were further checked and
verified in melanoma cells using immunofluorescence staining
(Figures 3C and 3F). Magnified cells inside the box clearly show
the reduced staining of nuclear b-catenin after the treatment of
cells with silymarin. As MMP-2 and MMP-9 are the downstream
targets of b-catenin [21–23], we also measured the effect of
silymarin on the levels of MMP-2 and MMP-9. Consistent with
the decreased nuclear localization of b-catenin after treating the
cells with silymarin, the expression of MMP-2 and MMP-9 were
also found to be decreased in both A375 and Hs294t cells after
treatment of the cells with silymarin for 24 h (Figures 3A and 3D).
Since, nuclear accumulation of b-catenin is inversely correlated
with phosphorylation at certain key residues of b-catenin (Ser
45,
Ser
33, Ser
37 and Thr
41), we checked the effect of silymarin on the
Figure 3. Effect of silymarin on b-catenin and its signaling molecules in melanoma cells. (A) Effect of silymarin on the cytosolic and nuclear
accumulation of b-catenin, and MMP-2 and MMP-9, which are downstream targets of b-catenin, in BRAF-mutated A375 cells. (B) Effect of silymarin on
phosphorylation of b-catenin at ‘‘critical residues’’ and on the expression levels of regulatory kinases (GSK-3b, CK1a) implicated in determining
nuclear/cytoplasmic accumulation of b-catenin. (C) Immunofluorescence staining shows decrease in nuclear accumulation of b-catenin in A375 cells
after the treatment of cells with silymarin for 24 h in a dose-dependent manner. Magnified nuclear staining is shown in the cells inside the box. (D)
The effect of silymarin on nuclear and cytosolic levels of b-catenin and its target MMPs proteins important for the cell migration in Hs294t cells after
the treatment of cells for 24 h. (E) Effect of silymarin on phosphorylation of b-catenin at ‘‘critical residues’’ and on the expression levels of regulatory
kinases (GSK-3b, CK1a) in metastasis-specific Hs294t cells. (F) Immunofluorescence staining showing decrease in nuclear accumulation of b-catenin in
Hs294t cells in a dose-dependent manner after treatment of cells with silymarin for 24 h. Magnified nuclear staining is shown in cells inside the box.
doi:10.1371/journal.pone.0023000.g003
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analysis revealed that treatment of A375 and Hs294t cells with
silymarin increased the phosphorylation of b-catenin at Ser
45, and
Ser
33/Ser
37/Thr
41 in both melanoma cell lines (Figures 3B and
3E). Further, silymarin treatment of melanoma cells resulted in a
dose-dependent increase of CK1a and GSK-3b. Both CK1a and
GSK-3b are known to target b-catenin for proteasomal degrada-
tion via combined phosphorylation at key residues of b-catenin
[12].
Silymarin enhances binding of b-TrCP to phospho forms
of b-catenin
It has been shown that b-transducin repeat-containing proteins
(b-TrCP) are components of the ubiquitin ligase complex targeting
b-catenin for proteasomal degradation and are thus a negative
regulator of Wnt/b-catenin signaling [24,25]. Therefore, we were
interested to check whether silymarin has any effect on the
expression levels or activity of b-TrCP in our melanoma invasion
model. For this purpose, A375 melanoma cells were treated with
silymarin for 24 h, cell lysates were prepared, and b-TrCP was
immunoprecipitated for detection of its binding with the phospho
forms of b-catenin. Western blot analysis data revealed that
silymarin did not affect the expression levels of b-TrCP after the
treatment of cells for 24 h (data not shown). However, treatment
of A375 cells with silymarin enhanced the binding of b-TrCP with
phospho forms of b-catenin in a dose-dependent manner, as
shown in Figure 4. These data suggest that silymarin may have
inactivated b-catenin by enhancing the proteasomal degradation
of the b-catenin after its binding with b-TrCP.
Specific activation of b-catenin leads to enhanced cell
migration
As we found that silymarin exerts a significant inhibitory effect
on the migration of A375 and Hs294t cells, and this inhibition was
associated with a decrease in nuclear accumulation of b-catenin in
both metastasis-specific melanoma cell lines, next we examined the
role of b-catenin in melanoma cell invasion. For this purpose we
selected two different melanoma cell lines: one was Mel 1241,
which possesses constitutively active Wnt/b-catenin signaling and
second one was Mel 1011 (lack activated b-catenin) from which
Mel 1241 was derived. First the cell migration ability of these two
melanoma cell lines was examined. Our preliminary analysis of
cell migration indicated that the cell migration ability of Mel 1241
cells after 24 h was exceptionally higher than A375 or Hs294t
cells. Therefore, we reduced the incubation period of the cells to
8 h for subsequent measurement of cell migration using the
invasion assay. As shown in Figure 5A, the cell migration activity
of Mel 1241 cells after 8 h was significantly higher than the cell
migration activity of the Mel 1011 cells. The number of migrating
cells of Mel 1241 cells was 499640 cells/microscopic filed whereas
the number of migrating cells of Mel 1011 cells were 2964 cells/
microscopic field, as summarized under Figure 5B (n=3).
Silymarin or FH535, an inhibitor of b-catenin, inhibits
melanoma cell invasion ability by targeting b-catenin
To examine whether silymarin inhibits melanoma cell migra-
tion by targeting b-catenin, cell migration experiment was
conducted with Mel 1241 and Mel 1011 cells with and without
the treatment of cells with various concentrations of silymarin (0,
10, 20, and 40 mg/mL) for 8 h. As shown in Figure 5C, treatment
of Mel 1241 cells with silymarin significantly inhibited (P,0.001)
the migration of Mel 1241 cells in a concentration-dependent
manner. Resultant cell migration data are summarized in terms of
mean number of migrating cells 6SD/microscopic field for
different treatment groups in Figure 5D. In contrast, silymarin did
not inhibit the cell migrating ability of Mel 1011 cells, which have
inactivated b-catenin (Figure 5E). In other words Mel 1011 cells
were resistant to the effect of silymarin on their cell migrating
behavior. A summary of migrating cells under different treatment
groups is shown in Figure 5F.
Further, in support of these observations, Mel 1241 and Mel
1011 cell lines were treated with various concentrations of FH535
(0, 20, 40 and 60 mM) for 8 h and cell migration was analyzed.
FH535 has unique ability to inhibit Wnt/b-catenin pathway [26].
As shown in Figure 6A, treatment of Mel 1241 cells with FH535
inhibited the migration of cells in a dose-dependent manner (40–
84%, P,0.001). Mean number of migrating cells per microscopic
field6 SD in different treatment groups are summarized in
Figure 6B (n=3). In contrast, FH535 did not inhibit the migration
of Mel 1011 cells or Mel 1011 cells were resistant to the effect of
FH535 on their cell migrating behavior (Figures 6C, 6D). These
data along with the data from silymarin treatment suggest that
activation of b-catenin stimulates melanoma cell invasion while its
inactivation suppresses the migration of melanoma cells.
In continuation with these studies, the effect of silymarin and
FH535 was also determined on the nuclear accumulation of b-
catenin, its down-stream targets (MMP-2 and MMP-9) and
phosphorylation of b-catenin at various Ser residues using Mel
1241 and Mel 1011 cell lines. For this purpose, cells were treated
with and without silymarin or FH535 for 8 h, and cell lysates were
prepared for western blot analysis. Western blot analysis revealed
that treatment of Mel 1241 cells with both silymarin or FH535 for
8 h resulted in reduced nuclear accumulation of b-catenin and
reduced levels of MMP-2 and MMP-9 compared to control cells
which were not treated with silymarin or FH535, as shown in
Figure 7A. Similarly, the phosphorylation of b-catenin at Ser
45,a n d
other target residues (Ser
33/Ser
37/Thr
41), and the levels of CK1a
and GSK-3b were increased after the treatment of Mel 1241 cells
with silymarin or FH535 (Figure 7B). However, these effects of
silymarin and FH535 were not observed in Mel 1011 cell line under
identical condition (data not shown) or the Mel 1011 melanoma
cells were resistant to the action of silymarin and FH535.
Combined effect of silymarin and FH535 on melanoma
cell (Mel 1241) invasion
We further checked the combined effect of silymarin and
FH535 on the invasion ability of Mel 1241 cells and this effect was
Figure 4. Treatment of melanoma cells with silymarin enhances
binding of b-TrCP with phospho forms of b-catenin. Cells were
treated with and without silymarin for 24 h and cell lysates were
prepared. In binding assay, b-TrCP was immunoprecipitated using
specific antibody from total protein lysates followed by western blot
analysis for phospho forms of b-catenin, as detailed in Materials and
Methods. IP, immunoprecipitation; IB, immunoblotting.
doi:10.1371/journal.pone.0023000.g004
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e23000Figure 5. Silymarin inhibits human melanoma cell migration by targeting b-catenin. (A), Comparison of invasion ability of two different
melanoma cell lines, one has stabilized mutation in b-catenin (Mel 1241) and another possesses wild-type b-catenin (Mel 1011). The migration
capacity of Mel 1241 cells after 8 h is significantly higher than the migration capacity of Mel 1011 cells. (B) The migratory cells were counted under
microscope and the results are summarized and expressed as the mean number of migratory cells 6 SD per microscopic field. Significant difference
versus Mel 1241 cells,
*P,0.001. (C), Treatment of Mel 1241 melanoma cells with silymarin for 8 h inhibits migration of Mel 1241 cells in a
concentration dependent manner. (D) The migratory cells were counted under microscope and the results are summarized and expressed as the
mean number of migratory cells 6 SD/microscopic field (n=3). Significant inhibition versus non-silymarin-treated control,
*P,0.001. (E) The effect of
silymarin on the Mel 1011 melanoma cell migration after the treatment for 8 h. (F) The migratory cells were counted under microscope in different
treatment groups and the results are summarized and expressed as the mean number of migratory cells 6 SD/microscopic field (n=3).
Representative photomicrographs of cell migration are shown from three identical experiments.
doi:10.1371/journal.pone.0023000.g005
Figure 6. Effect of FH535, an inhibitor of b-catenin, on melanoma cell migration. (A) Mel 1241 cells were incubated with FH535 for 8 h and
cell migration was determined using invasion assay. FH535 inhibits the cell migration of Mel 1241 cells in a dose-dependent manner. (B) The
migratory cells were counted on the membrane under microscope and the results are expressed as the mean number of migratory cells 6 SD per
microscopic field. Significant inhibition versus control,
*P,0.001,
**P,0.01. (C) Treatment of Mel 1011 cells with FH535 for 8 h did not inhibit cell
migration compared to non-FH535-treated control. (D) Migratory cells were counted under microscope and the results are expressed as the mean
number of migratory cells6 SD per microscopic field. Migration assays were repeated three times and representative pictures of cell migration are
shown. No statistical significance of difference versus un-treated controls.
doi:10.1371/journal.pone.0023000.g006
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these cells using identical cell invasion protocol. As shown in
Figure 7C, treatment of Mel 1241 cells with low doses of silymarin
(20 mg/mL) and FH535 (20 mM) separately for 8 h inhibited the
cell migration respectively by 54% and 40% compared to non-
treated control cells. However, the invasion activity of Mel 1241
cells was significantly inhibited (81%, P,0.01) when the cells were
treated with silymarin plus FH535 compared with either agent
alone, as shown in Figure 7C.
Discussion
The significant findings of the present study are that silymarin
inhibits invasion or cell migration ability of melanoma cells in a
dose-dependent manner, and that is associated with the inactiva-
tion of b-catenin signaling pathway. Based on our observation,
cells will go under apoptosis or cell death if melanoma cells are
treated with silymarin for more than 24 h time period or at a
higher concentration of silymarin (.40 mg/mL). Under these
conditions, cell migration will decrease, and this reduction in cell
migration could be due to reduced cell viability or cell death and
not because of changes in migrating behavior of cells. In our study,
cell death or apoptosis is not a reason of silymarin-caused
inhibition of melanoma cell migration. Silymarin has been shown
to inhibit skin carcinogenesis [4–6], and has pleiotropic activities
which include the inhibition of cyclooxygenase-2 (COX-2) activity
and an inhibitor of polyamine biosynthesis [4,5]. Traditional non-
steroidal anti-inflammatory drugs (NSAIDs), such as sulindac,
inhibit COX-2 expression resulting in reduced Wnt-signaling by
induced b-catenin degradation, as has been shown in colon cancer
[27]. Similar to the function of NSAIDs, silymarin also induced b-
catenin degradation in melanoma cells and that is associated with
inhibition of melanoma cell migration.
Various studies have implicated the role of constitutively active
Wnt/b-catenin signaling in tumor progression. b-catenin is a dual
function protein and is an important component of cell-cell
adhesion, where it forms a dynamic link between E-cadherin and
cytoskeleton [28,29]. This cell-to-cell adhesion may prevent the
migration of cells. However, the breaking of cell-to-cell adhesion
due to activation of b-catenin and its nuclear accumulation may
increase the migration potential of tumor cells. It can also regulate
cell migration via its role as a transcription factor wherein it along
with transcription factors of the T-cell factor and lymphoid
enhancer factor family regulates expression of various target genes
that mediate cellular processes including cell migration [11]. Thus
nuclear/cytoplasmic ratio of b-catenin in the cells determines their
migration potential. Our results show that silymarin inhibits
melanoma cell migration by targeting b-catenin. It has been
shown that phosphorylation of b-catenin at critical target residues
such as at Ser
45, Ser
33/37 and Thr
41 by GSK-3b and CK1a within
the cytosolic destruction complex leads to degradation of b-catenin
and thus reduces its nuclear accumulation [12]. In our study, we
found that treatment of melanoma cells with silymarin enhances
the expression of GSK-3b and CK1a, and b-catenin is
Figure 7. Effect of silymarin and FH535 on b-catenin and its signaling molecules in Mel 1241 cells. (A) Effect of silymarin and FH535 on
the cytosolic and nuclear accumulation of b-catenin, and MMP-2 and MMP-9 in Mel 1241 cells. Cells were treated with silymarin or FH535 for 8 h then
harvested, nuclear and cytosolic fractions were prepared and subjected to western blot analysis. (B) Effect of silymarin and FH535 on phosphorylation
of b-catenin at ‘‘critical residues’’ and on the expression levels of regulatory kinases (GSK-3b, CK1a) implicated in activation of b-catenin. (C) The
combined effect of silymarin and FH535 on Mel 1241 cell migration. Cells were treated with the indicated low doses of silymarin and FH535 either
alone or in combination for 8 h and cell migration was determined using invasion assay. Cell migration data are expressed as the mean number of
migratory cells 6SD per microscopic field (n=3). Significant inhibition versus untreated control,
*P,0.001,
*P,0.01. Significant inhibition versus either
agent alone,
"P,0.01.
doi:10.1371/journal.pone.0023000.g007
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silymarin via enhanced expression of GSK-3b and CK1a leads to
enhanced phosphorylation of b-catenin at critical residues. This
then lead to degradation of b-catenin within the degradation
complex resulting in its reduced nuclear accumulation. It thus
explains inhibitory effects of silymarin against melanoma cell
migration.
Diverse molecular events are integrated in the progression and
metastasis of cancer cells. In tumor cells, mechanisms that inhibit
GSK-3b-induced phosphorylation of b-catenin block its interaction
with the E3 ubiquitin ligase receptor, b-TrCP, which prevents b-
catenin ubiquitination and degradation, and ultimately leads to b-
cateninactivation [24,25].Oncogenicactivation ofb-cateninoccurs
primarily as a consequence of its stabilization by escaping ubiquitin-
mediated proteasomal degradation. A major regulator of b-catenin
stability and activity is the b-TrCP. In this study, we sought to
determine whether the inactivation of b-catenin in melanoma cells
by silymarin is affected by expression of its regulator, the b-TrCP.
We found that silymarin enhanced the binding of b-TrCP to
phospho forms of b-catenin, which suggests b-TrCP-mediated
ubiquitination and degradation/inactivation of b-catenin [25,30].
Thus, this finding further supports our hypothesis that silymarin
inhibits melanoma cell migration by targeting b-catenin.
In an attempt to further verify the role of silymarin on
prevention of invasive potential of melanoma cell through
inactivation of b-catenin signaling, we used two distinct melanoma
cell lines, namely Mel 1241 and Mel 1011. The two cell lines differ
in status of constitutive activation of Wnt/b-catenin signaling. Our
preliminary data show that Mel 1241 melanoma cells which
possess constitutively active Wnt/b-catenin are highly invasive and
the capacity of cell migration is multiple-fold higher than A375
and Hs294t cell lines. Treatment of Mel 1241 cells with silymarin
resulted in significant inhibition of cell migration which was
associated with the reduction in nuclear accumulation of b-catenin
and reduction in the levels of MMP-2 and MMP-9 which are the
down-stream targets of b-catenin signaling. These observations
were supported when treatment of these cells with FH535, an
inhibitor b-catenin, also resulted in significant inhibition of Mel
1241 cell migration concomitantly reduced accumulation of
nuclear b-catenin and lowering the levels of MMPs. Both
silymarin and FH535 elevated the levels of GSK-3b and CK1a
and simultaneously enhances the phosphorylation of b-catenin at
specific target residues (e.g., Ser
45, Ser
33/37 and Thr
41). Both CK1a
and GSK-3b are known to target b-catenin for proteasomal
degradation via combined phosphorylation at key residues of b-
catenin [12]. Interestingly, under identical experimental condi-
tions, these effects of silymarin and FH535 were not found in the
Mel 1011 cell line, which lacks constitutively active b-catenin. Wnt
signaling is suggested to inhibit b-catenin phosphorylation, thus
inducing the accumulation of cytosolic b-catenin, which associates
with the T cell factor/lymphocyte enhancer factor family of
transcription factors to activate Wnt/b-catenin-responsive genes
[31,32]. Our study provide evidence that silymarin induced b-
catenin phosphorylation degradation in melanoma cells is
associated with the up-regulation of CK1a and GSK-3b. Liu
et al. [12] have identified CK1a as an essential component that
controls b-catenin phosphorylation degradation in Drosophila.
In summary, the outcome of this study suggests that silymarin
has the ability to block or inhibit the invasive potential of
melanoma cells, and this anti-invasion effect of silymarin is
mediated through inactivation of b-catenin, as summarized under
Figure 8. Thus intervention strategies targeting key molecules of
the Wnt/b-catenin pathway may represent promising approaches
to inhibit metastasis of melanoma cells. This new insight into the
anti-melanoma cell migration activity of silymarin could serve as
the basis for chemoprevention or therapy of malignant melanoma
in high risk individuals.
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